View More Recent Stories

Aug 11, 2022 07:00AM Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Aug 11, 2022 07:00AM Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Jul 5, 2022 07:00AM Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
Jul 5, 2022 07:00AM Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
May 12, 2022 05:08PM Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
May 12, 2022 05:08PM Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
May 9, 2022 07:00AM Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 9, 2022 07:00AM Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 5, 2022 08:00AM Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
May 5, 2022 08:00AM Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
May 2, 2022 08:00AM Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET
May 2, 2022 08:00AM Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET
Feb 28, 2020 07:00AM Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
Feb 28, 2020 07:00AM Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
View More Recent Stories